Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
On May 12, 2026, we issued a press
release regarding our financial results for the three months ended March 31, 2026. A copy of the press release is furnished herewith as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
As provided in General Instruction
B-2 of SEC Form 8-K, the information set forth in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed”
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended (the “Securities Act”), or the Exchange Act, whether made before or after the date hereof, except as expressly set
forth by specific reference in such filing to this Current Report on Form 8-K.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Exhibit 99.1
Earnings Release
Paysign’s Patient Affordability Drives 51% Revenue Growth and
Significant Margin Expansion for First Quarter 2026
Mix Shift Continues to Deliver Expansion in Gross and Operating Margin
Strong Balance Sheet Enables Continued Investment for Profitable Growth
HENDERSON, Nev. – May 12, 2026 – (Business Wire) –
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability offerings, donor compensation solutions, engagement and
management platforms and integrated payment processing for the life sciences industries, today announced financial results for the first
quarter 2026.
First Quarter 2026 Financial Highlights
| |
· |
First quarter 2026 revenues of $28.04 million, up 50.8% from first quarter 2025 |
| |
|
|
| |
· |
First quarter 2026 pharma revenue increased to $15.68 million, an increase of 81.9% versus first quarter 2025; added 45 net patient affordability programs during the past twelve months, exiting the quarter with 135 active programs |
| |
|
|
| |
· |
First quarter 2026 plasma revenue increased to $11.75 million, an increase of 24.9% versus first quarter 2025; total net plasma center count increased by 89 during the past 12 months, exiting the quarter with 573 centers |
| |
|
|
| |
· |
First quarter 2026 operating margin was 23.8% compared to 13.4% in the first quarter 2025 |
| |
|
|
| |
· |
First quarter 2026 net income of $5.44 million, or $0.09 per diluted share, versus net income of $2.59 million, or $0.05 per diluted share in the first quarter 2025 |
| |
|
|
| |
· |
First quarter 2026 adjusted EBITDA of $10.59 million, up 113.4% from $4.96 million for first quarter 2025; diluted Adjusted EBITDA per share of $0.17 versus $0.09 for first quarter 20251 |
| |
|
|
| |
· |
Exited the quarter with $20.55 million of unrestricted cash and zero bank debt |
| |
|
|
| |
· |
First quarter 2026 restricted cash balances increased 10.4% to $158.95 million from first quarter 2025 |
| |
|
|
| |
· |
First quarter 2026 gross dollar load volume was up 26.4% versus first quarter 2025 |
| |
|
|
| |
· |
First quarter 2026 gross spend volume was up 26.7% versus first quarter 2025 |
| |
|
|
1Adjusted EBITDA and Adjusted EBITDA per share are
non-GAAP metrics used by management to gauge the operating performance of the business – see reconciliation of net income to Adjusted
EBITDA at the end of the press release.
“Paysign delivered a strong start to 2026, with exceptional
top- and bottom-line results that are consistent with our strategic direction and the scalability of the platform we’ve
built,” said Mark Newcomer, President and CEO of Paysign. “Our plasma donor compensation business continues to perform
exceptionally well, and the reception to our SaaS solutions from collectors and plasmapheresis manufacturers across the U.S., Europe
and Asia reinforces our conviction that purpose-built technology, backed by deep industry expertise, creates a competitive
advantage. Patient affordability emerged as our largest revenue contributor in the quarter, with 135 active programs and a strong
pipeline that reflects the trust pharmaceutical manufacturers place in Paysign to help patients access and afford the therapies they
need. As this business grows, we are positioned to deliver long-term value for our shareholders, our customers and the patients we
serve.”
2026 First Quarter Results
Total revenues increased 50.8%, or $9.44 million, to $28.04 million,
up from $18.6 million in the first quarter of 2025. Pharma industry revenue increased 81.9% to $15.68 million from $8.62 million due to
the financial benefit of 45 net pharma patient affordability programs launched during the past 12 months, and a corresponding increase
in monthly management fees, setup fees, claim processing fees and other billable services such as dynamic business rules and customer
service contact center support. Processed claims increased by approximately 49% compared to the first quarter of 2025. Plasma revenue
increased 24.9% to $11.75 million, up from $9.41 million, primarily due to the addition of 89 net plasma centers added during the past
12 months. The average monthly revenue per center increased to $6,671 versus $6,517 and the average number of loads per center increased
for the first time since the industry experienced an inventory correction that began in 2024. We exited the quarter with 573 centers versus
595 centers at the end of 2025 as 20 centers were sold to companies who use a competing provider and two underperforming centers were
closed. Combined, these centers averaged less than $3,500 per month in revenue, performing below the corporate average.
Cost of revenues increased 42.2% due to increased call center support
expense associated with the revenue growth, a new customer service contact center that went live in November 2025 and higher employee
costs. Gross profit improved to 65.0% compared to 62.9% in the first quarter of 2025 as we experienced a greater mix of pharma revenue.
Total operating expenses were $11.55 million compared to $9.20 million
in the first quarter of 2025, an increase of 25.5%. Selling, general and administrative expenses increased by 20.5% to $8.91 million.
Of that amount, stock compensation expense increased 91.0% to $1.28 million. Depreciation and amortization increased by $835 thousand,
or 46.4%, due mainly to the amortization of intangible assets from our Gamma acquisition and continued capitalization of new software
development costs and equipment purchases related to the enhancement to our processing platform. Operating margin was 23.8% compared to
13.4% in the first quarter of 2025.
The company recorded an income tax provision of $2.03 million, resulting
in an effective tax rate of 27.2%, up $1.36 million from the first quarter of 2025 and a tax rate of 20.5%. The effective tax rates reflect
adjustments for discrete quarterly items and tax benefits from stock-based compensation. The significant driver in the discrete item adjustment
in the first quarter of 2026 was primarily related to the increase in stock price at March 31, 2026, when compared to the same period
in the prior year.
Net income for the quarter totaled $5.44 million, or $0.09 per fully
diluted share, an increase of 110.3% from $2.59 million, or $0.05 per fully diluted share, reported in the first quarter of 2025. On a
non-GAAP basis, EBITDA, defined as earnings before interest, taxes, depreciation and amortization, increased by $5.01 million, or 116.9%,
to $9.30 million. Adjusted EBITDA, which excludes stock-based compensation from EBITDA and is used by management to evaluate core operating
performance, rose $5.63 million, or 113.4%, to $10.59 million, or $0.17 per fully diluted share.
Balance Sheet at March 31, 2026
The company’s cash flows increased $14.51 million from December
31, 2025, largely related to the improvement in our operating results, growth of existing customer programs and the launch of new customer
programs.
During the first quarter of 2026, unrestricted cash decreased by $523
thousand to $20.55 million. The decline was attributable to the timing of operating asset and liability payments, capital investments
in intangible and fixed assets and payments of other liabilities associated with the Gamma acquisition. Offsetting these cash outflows
were net income and non-cash adjustments.
Restricted cash increased $15.03 million to $158.95 million from December
31, 2025, primarily related to customer program deposits for our plasma and pharma customers of $9.71 million and an increase in funds
on card of $5.32 million. Restricted cash are funds used for customer card funding and pharmaceutical claim reimbursements with a corresponding
offset under current liabilities.
2026 Outlook
“Our first quarter results exceeded guidance across every line
of the income statement,” commented Jeff Baker, Chief Financial Officer of Paysign. “Revenue, operating margin and net income
all finished above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift toward patient affordability.
We are reiterating our full-year 2026 ranges, and the momentum from the first quarter supports our confidence in achieving the upper
half of our guidance ranges.”
“The table below details our second quarter and full-year 2026
outlook,” continued Baker. “The second quarter reflects the seasonal pattern we have laid out previously: pharma revenue is
highest in the first quarter as patient affordability claims peak, and plasma builds through the balance of the year. For the full year,
we continue to expect plasma and pharma to contribute roughly equally to revenue, with margins expanding across the income statement and
net income nearly doubling over 2025 as patient affordability scales. With a strong unrestricted cash position, no bank debt and a growing
cash flow profile, we are well positioned to fund our 2026 investment plans and execute against the financial framework we have communicated.”
| |
Second Quarter 2026 |
Full Year 2026 |
| Revenue |
$26.2M – $26.7M |
$106.5M – $110.5M |
| Revenue growth (YoY) |
37.5% – 40.0% |
30% – 35% |
| Gross margin |
60.0% – 62.0% |
60% – 62% |
| Net income |
$3.5M – $4.0M |
$13.0M – $16.0M |
| Diluted EPS |
$0.06 – $0.07 |
$0.21 – $0.26 |
| Adjusted EBITDA2 |
$7.7M – $8.5M |
$30.0M – $33.0M |
| Adj. EBITDA per diluted share2 |
$0.13 – $0.14 |
$0.49 – $0.53 |
Paysign expects to exit the second quarter of 2026 with 147–150
active patient affordability programs and 555–560 plasma centers.
2 The company is unable to provide a reconciliation
of forward-looking adjusted EBITDA, adjusted EBITDA per diluted share and adjusted EBITDA margin to the most directly comparable GAAP
measure, net income (and net income per diluted share), without unreasonable effort due to the variability, complexity and low visibility
of certain reconciling items. These items include, but are not limited to, stock-based compensation and other non-recurring items, which
could have a material impact on GAAP results.
First Quarter 2026 Financial Results Conference Call Details
The company will hold a conference call at 5:00 p.m. Eastern time on
Tuesday, May 12, 2026, to discuss its first quarter 2026 financial results. The conference call may include forward-looking statements.
The dial-in information for this call is 877.407.2988 (within the U.S.) and +1.201.389.0923 (outside the U.S.). A call replay will be
available until August 12, 2026, and can be accessed by dialing 877.660.6853 (within the U.S.) and +1.201.612.7415 (outside the U.S.),
using passcode 13760115.
Forward-Looking Statements
Certain statements in this press release may be considered forward-looking
under federal securities laws, and we intend that such forward-looking statements be subject to the safe harbor created thereby. All statements,
besides statements of fact included in this release are forward-looking. Such forward-looking statements include, among others, our belief
that we delivered a strong start to 2026, with exceptional top- and bottom-line results that are consistent with our strategic direction
and the scalability of the platforms we’ve built; our belief that our plasma donor compensation business continues to perform exceptionally
well, and the reception to our SaaS solutions from collectors and plasmapheresis manufacturers across the U.S., Europe and Asia reinforces
our conviction that purpose-built technology, backed by deep industry expertise, creates a competitive advantage; our belief that patient
affordability emerged as our largest revenue contributor in the quarter, with 135 active programs and a strong pipeline that reflects
the trust pharmaceutical manufacturers place in us to help patients access and afford the therapies they need; our belief that as this
business grows, we are positioned to deliver long-term value for our shareholders, our customers and the patients we serve; our belief
that our first quarter results exceeded guidance across every line of the income statement; our belief that revenue, operating margin
and net income all finished above the high end of our prior ranges, driven by fixed cost leverage and a continued mix shift toward patient
affordability; our belief that the full-year 2026 ranges, and the momentum from the first quarter supports our continued confidence in
our full-year guidance ranges; our belief that the second quarter reflects the seasonal pattern we have laid out previously: pharma revenue
is highest in the first quarter as patient affordability claims peak, and plasma builds through the balance of the year; our belief that
for the full year, we will continue to expect plasma and pharma to contribute roughly equally to revenue, with margins expanding across
the income statement and net income nearly doubling over 2025 as patient affordability scales; our belief that with a strong unrestricted
cash position, no debt and a growing cash flow profile, we are well positioned to fund our 2026 investment plans and execute against the
financial framework we have communicated; our expectation that we will exit the second quarter of 2026 with 147–150 active patient
affordability programs and 555–560 plasma centers; our belief that non-GAAP measures used by management to gauge the operating performance
of the business help investors better evaluate our past financial performance and potential future results; and our expectations for total
revenues, gross profit margins, operating expenses, depreciation and amortization expenses, stock-based compensation expense, interest
income, tax rate, fully diluted share count, net income, net margin, Adjusted EBITDA and Adjusted EBITDA margin for the second quarter
and full-year 2026. We caution that these statements are qualified by important risks, uncertainties and other factors that could cause
actual results to differ materially from those reflected by such forward-looking statements. Such factors include, among others, the inability
to continue our current growth rate in future periods; the risk that we may not be able to add new patient affordability programs or retain
existing programs at anticipated rates; the risk that plasma center customers may switch to competing providers or close centers, reducing
our revenue; the risk that our outlook and guidance may not be achieved due to factors within or outside our control; that a downturn
in the economy could reduce our customer base and demand for our products and services, which could have an adverse effect on our business,
financial condition, profitability and cash flows; operating in a highly regulated environment; failure by us or business partners to
comply with applicable laws and regulations; changes in the laws, regulations, credit card association rules or other industry standards
affecting our business; changes in the regulatory or legislative environment affecting pharmaceutical patient affordability or copay assistance
programs, including potential restrictions on copay accumulator or maximizer programs; that a data security breach could expose us to
liability and protracted and costly litigation; risks related to the integration of acquisitions, including the Gamma acquisition, and
the realization of anticipated benefits therefrom; and other risk factors set forth in our Annual Report on Form 10-K for the year ended
December 31, 2025. Except to the extent required by federal securities laws, the company undertakes no obligation to publicly update or
revise any statements in this release, whether as a result of new information, future events or otherwise.
About Paysign, Inc.
Paysign, Inc. (NASDAQ: PAYS) operates at the intersection of fintech and
healthcare, integrating advanced payment processing and program management with tailored technologies for the plasma, pharmaceutical and
life sciences industries. Their breakthrough patient affordability solutions ensure patients receive the financial assistance they need
to adhere to prescribed therapies by mitigating the effects of copay accumulators and maximizers. Paysign specializes in blood and plasma
donor compensation programs, as well as comprehensive engagement and management platforms optimized for life sciences. Paysign’s
proprietary processing architecture supports physical, virtual, mobile and bank-based payments with real-time transaction intelligence,
enabling efficient, compliant and scalable program delivery. Through advanced reporting, analytics and in-house 24/7 bilingual customer
support, Paysign delivers measurable value, exceptional service and a superior experience for donors, patients, healthcare providers,
pharmaceutical manufacturers and program sponsors across their growing fintech healthcare ecosystem. The company is committed to improving
efficiencies, reducing costs, streamlining communications, increasing program performance and providing actionable insights to those they
serve.
Contacts:
|
Investor Relations:
888.522.4810
paysign.com/investors
ir@paysign.com |
Media Relations:
Alicia Ches
888.522.4850
pr@paysign.com |
Paysign, Inc.
Condensed Consolidated Statements of Operation (Unaudited)
| | |
| | |
| |
| | |
Three Months Ended March 31, | |
| | |
2026 | | |
2025 | |
| Revenues | |
| | | |
| | |
| Plasma industry | |
$ | 11,748,611 | | |
$ | 9,409,880 | |
| Pharma industry | |
| 15,679,452 | | |
| 8,618,653 | |
| Other | |
| 610,361 | | |
| 569,616 | |
| Total revenues | |
| 28,038,424 | | |
| 18,598,149 | |
| | |
| | | |
| | |
| Cost of revenues | |
| 9,819,479 | | |
| 6,907,321 | |
| | |
| | | |
| | |
| Gross profit | |
| 18,218,945 | | |
| 11,690,828 | |
| | |
| | | |
| | |
| Operating expenses | |
| | | |
| | |
| Selling, general and administrative | |
| 8,914,654 | | |
| 7,400,759 | |
| Depreciation and amortization | |
| 2,636,156 | | |
| 1,801,003 | |
| Total operating expenses | |
| 11,550,810 | | |
| 9,201,762 | |
| | |
| | | |
| | |
| Income from operations | |
| 6,668,135 | | |
| 2,489,066 | |
| | |
| | | |
| | |
| Other income | |
| | | |
| | |
| Interest income, net | |
| 800,863 | | |
| 762,198 | |
| | |
| | | |
| | |
| Income before income tax provision | |
| 7,468,998 | | |
| 3,251,264 | |
| Income tax provision | |
| 2,030,080 | | |
| 665,164 | |
| | |
| | | |
| | |
| Net income | |
$ | 5,438,918 | | |
$ | 2,586,100 | |
| | |
| | | |
| | |
| Net income per share | |
| | | |
| | |
| Basic | |
$ | 0.10 | | |
$ | 0.05 | |
| Diluted | |
$ | 0.09 | | |
$ | 0.05 | |
| | |
| | | |
| | |
| Weighted average common shares | |
| | | |
| | |
| Basic | |
| 55,167,911 | | |
| 53,576,030 | |
| Diluted | |
| 61,022,060 | | |
| 55,142,511 | |
Paysign, Inc.
Condensed Consolidated Balance Sheets
| | |
| | |
| |
| | |
March 31,
2026 (Unaudited) | | |
December 31,
2025 (Audited) | |
| ASSETS | |
| | | |
| | |
| Current assets | |
| | | |
| | |
| Cash | |
$ | 20,545,119 | | |
$ | 21,067,651 | |
| Restricted cash | |
| 158,950,332 | | |
| 143,917,060 | |
| Accounts receivable, net | |
| 94,248,593 | | |
| 72,191,994 | |
| Other receivables | |
| 345,228 | | |
| 926,529 | |
| Prepaid expenses and other current assets | |
| 3,265,549 | | |
| 1,953,717 | |
| Total current assets | |
| 277,354,821 | | |
| 240,056,951 | |
| | |
| | | |
| | |
| Fixed assets, net | |
| 2,007,393 | | |
| 1,897,892 | |
| Intangible assets, net | |
| 21,675,898 | | |
| 22,346,213 | |
| Goodwill | |
| 4,487,637 | | |
| 4,487,637 | |
| Operating lease right-of-use asset | |
| 5,522,775 | | |
| 5,729,541 | |
| Deferred tax asset, net | |
| 1,677,104 | | |
| 1,734,969 | |
| | |
| | | |
| | |
| Total assets | |
$ | 312,725,628 | | |
$ | 276,253,203 | |
| | |
| | | |
| | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts payable and accrued liabilities | |
$ | 87,539,193 | | |
$ | 70,542,803 | |
| Customer card funding | |
| 158,112,295 | | |
| 143,191,068 | |
| Operating lease liability, current portion | |
| 871,495 | | |
| 751,503 | |
| Other liabilities, current portion | |
| 1,585,985 | | |
| 1,863,116 | |
| Total current liabilities | |
| 248,108,968 | | |
| 216,348,490 | |
| | |
| | | |
| | |
| Operating lease liability, long-term portion | |
| 5,048,579 | | |
| 5,273,891 | |
| Other liabilities, long-term portion | |
| 4,554,666 | | |
| 6,140,651 | |
| | |
| | | |
| | |
| Total liabilities | |
| 257,712,213 | | |
| 227,763,032 | |
| | |
| | | |
| | |
| Common stock; $0.001 par value; 150,000,000 shares authorized, 56,732,596 and 56,021,596 issued at March 31, 2026 and December 31, 2025, respectively | |
| 56,733 | | |
| 56,022 | |
| Additional paid-in capital | |
| 36,786,545 | | |
| 35,503,253 | |
| Treasury stock at cost, 990,955 and 934,708 shares, respectively | |
| (2,348,392 | ) | |
| (2,148,715 | ) |
| Retained earnings | |
| 20,518,529 | | |
| 15,079,611 | |
| Total stockholders’ equity | |
| 55,013,415 | | |
| 48,490,171 | |
| | |
| | | |
| | |
| Total liabilities and stockholders’ equity | |
$ | 312,725,628 | | |
$ | 276,253,203 | |
Paysign, Inc. Non-GAAP Measures
To supplement Paysign’s financial results presented on a GAAP basis,
we use non-GAAP measures that exclude from net income the following cash and non-cash items: interest, taxes, depreciation and amortization
and stock-based compensation. We believe these non-GAAP measures used by management to gauge the operating performance of the business
help investors better evaluate our past financial performance and potential future results. Non-GAAP measures should not be considered
in isolation or as a substitute for comparable GAAP accounting, and investors should read them in conjunction with the company’s
financial statements prepared in accordance with GAAP. The non-GAAP measures we use may be different from, and not directly comparable
to, similarly titled measures used by other companies.
“EBITDA” is defined as earnings before interest, taxes, depreciation
and amortization expense. “Adjusted EBITDA” reflects the adjustment to EBITDA to exclude stock-based compensation charges.
EBITDA and Adjusted EBITDA are not intended to represent cash flows from
operations, operating income or net income as defined by U.S. GAAP as indicators of operating performances. Management cautions that amounts
presented in accordance with Paysign’s definition of Adjusted EBITDA may not be comparable to similar measures disclosed by other
companies because not all companies calculate Adjusted EBITDA in the same manner.
Paysign, Inc.
Adjusted EBITDA (Unaudited)
| | |
Three Months Ended | |
| | |
March 31, | |
| | |
2026 | | |
2025 | |
| Reconciliation of EBITDA and Adjusted EBITDA to net income: | |
| | | |
| | |
| Net income | |
$ | 5,438,918 | | |
$ | 2,586,100 | |
| Income tax provision | |
| 2,030,080 | | |
| 665,164 | |
| Interest income, net | |
| (800,863 | ) | |
| (762,198 | ) |
| Depreciation and amortization | |
| 2,636,156 | | |
| 1,801,003 | |
| EBITDA | |
| 9,304,291 | | |
| 4,290,069 | |
| Stock-based compensation | |
| 1,284,003 | | |
| 672,318 | |
| Adjusted EBITDA | |
$ | 10,588,294 | | |
$ | 4,962,387 | |
| | |
| | | |
| | |
| Adjusted EBITDA per share | |
| | | |
| | |
| Basic | |
$ | 0.19 | | |
$ | 0.09 | |
| Diluted | |
$ | 0.17 | | |
$ | 0.09 | |
| | |
| | | |
| | |
| Weighted average common shares | |
| | | |
| | |
| Basic | |
| 55,167,911 | | |
| 53,576,030 | |
| Diluted | |
| 61,022,060 | | |
| 55,142,511 | |
“EBITDA margin” is defined as earnings before interest,
income taxes, depreciation and amortization expense as a percentage of the company’s revenue and “Adjusted EBITDA margin”
reflects the adjustment to EBITDA margin to exclude stock-based compensation expense as a percentage of revenue. A reconciliation of net
income margin to Adjusted EBITDA margin is provided in the table below.
| | |
Three Months Ended
March 31, | |
| | |
2026 | | |
2025 | |
| Reconciliation of adjusted EBITDA margin to net income margin: | |
| | | |
| | |
| Net income margin | |
| 19.4% | | |
| 13.9% | |
| Income tax provision | |
| 7.2% | | |
| 3.6% | |
| Interest income, net | |
| (2.9% | ) | |
| (4.1% | ) |
| Depreciation and amortization | |
| 9.4% | | |
| 9.7% | |
| EBITDA margin | |
| 33.2% | | |
| 23.1% | |
| Stock-based compensation | |
| 4.6% | | |
| 3.6% | |
| Adjusted EBITDA margin | |
| 37.8% | | |
| 26.7% | |
